» Articles » PMID: 32747398

Feasibility and Clinical Impact of Out-of-ICU Noninvasive Respiratory Support in Patients with COVID-19-related Pneumonia

Abstract

Introduction: The severe acute respiratory syndrome-coronavirus 2 outbreak spread rapidly in Italy and the lack of intensive care unit (ICU) beds soon became evident, forcing the application of noninvasive respiratory support (NRS) outside the ICU, raising concerns over staff contamination. We aimed to analyse the safety of the hospital staff and the feasibility and outcomes of NRS applied to patients outside the ICU.

Methods: In this observational study, data from 670 consecutive patients with confirmed coronavirus disease 2019 referred to pulmonology units in nine hospitals between March 1 and May 10, 2020 were analysed. Data collected included medication, mode and usage of NRS ( high-flow nasal cannula (HFNC), continuous positive airway pressure (CPAP), noninvasive ventilation (NIV)), length of stay in hospital, endotracheal intubation (ETI) and deaths.

Results: 42 (11.1%) healthcare workers tested positive for infection, but only three of them required hospitalisation. Data are reported for all patients (69.3% male), whose mean±sd age was 68±13 years. The arterial oxygen tension/inspiratory oxygen fraction ratio at baseline was 152±79, and the majority (49.3%) of patients were treated with CPAP. The overall unadjusted 30-day mortality rate was 26.9%, with 16%, 30% and 30% for HFNC, CPAP and NIV, respectively, while the total ETI rate was 27%, with 29%, 25% and 28%, respectively; the relative probability of death was not related to the NRS used after adjustment for confounders. ETI and length of stay were not different among the groups. Mortality rate increased with age and comorbidity class progression.

Conclusions: The application of NRS outside the ICU is feasible and associated with favourable outcomes. Nonetheless, it was associated with a risk of staff contamination.

Citing Articles

'Do-not-intubate' orders in patients assisted by noninvasive respiratory support for acute hypoxaemic failure caused by coronavirus disease 2019; a systematic review and meta-analysis.

Cammarota G, Esposito T, Simonte R, Messina A, Cecconi M, Vaschetto R Eur J Anaesthesiol Intensive Care. 2025; 2(1):e0018.

PMID: 39916762 PMC: 11783619. DOI: 10.1097/EA9.0000000000000018.


Evaluating the impact of ESICM 2023 guidelines and the new global definition of ARDS on clinical outcomes: insights from MIMIC-IV cohort data.

Song D, Chen Q, Huang S, Qiu S, Chen Z, Cai Y Eur J Med Res. 2025; 30(1):51.

PMID: 39849624 PMC: 11755903. DOI: 10.1186/s40001-025-02289-w.


CPAP delivered via a helmet interface in lightly sedated patients with moderate to severe ARDS: predictors of success outside the ICU.

Matos I, Tomaz B, Sales M, Gomes G, Brazil Viana Junior A, Goncalves M J Bras Pneumol. 2024; 50(5):e20240299.

PMID: 39661843 PMC: 11601069. DOI: 10.36416/1806-3756/e20240299.


Oxygenation indices and early prediction of outcome in hypoxemic patients with COVID-19 pneumonia requiring noninvasive respiratory support in pulmonary intermediate care unit.

Scala R, Renda T, Bambina S, Guidelli L, Arniani S, Carrassa L Pneumonia (Nathan). 2024; 16(1):22.

PMID: 39582005 PMC: 11587655. DOI: 10.1186/s41479-024-00145-9.


Oxygen therapy and noninvasive respiratory supports in acute hypoxemic respiratory failure: a narrative review.

Thille A, Balen F, Carteaux G, Chouihed T, Frat J, Girault C Ann Intensive Care. 2024; 14(1):158.

PMID: 39419924 PMC: 11486880. DOI: 10.1186/s13613-024-01389-w.


References
1.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

2.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

3.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

4.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

5.
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M . Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; 323(16):1612-1614. PMC: 7082763. DOI: 10.1001/jama.2020.4326. View